首页> 外文期刊>Cell biology international. >H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo
【24h】

H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo

机译:H19 / MIR-107 / HMGB1轴通过在体外和体内抑制自噬抑制自噬,使喉鳞状细胞癌致敏于顺铂

获取原文
获取原文并翻译 | 示例
           

摘要

Laryngeal squamous cell carcinoma (LSCC) is the most common malignant tumor, which occurs in the head and neck. Current treatments for LSCC are all largely weakened by increasing drug resistance. Our study aimed to investigate the effects of long noncoding RNA (lncRNA) H19 on drug resistance in LSCC. In our study, we found that the level of H19 was sharply upregulated in LSCC tissues and drug-resistant cells compared with the control. Besides, the expression of high-mobility group B1 (HMGB1) was elevated, and microRNA107 (miR-107) was suppressed in drug-resistant cells compared with the control. Further study revealed that the interference of H19 by short hairpin RNA (shRNA) effectively suppressed high autophagy level and obvious drug resistance in drug-resistant cells. Besides that, miR-107 was predicted as a target of H19 and inhibiting effects of H19 shRNA on autophagy and drug resistance were both reversed by miR-107 inhibitor. Moreover, HMGB1 was predicted as a target of miR-107 in LSCC cells and knockdown of HMGB1 was able to suppress autophagy and drug resistance in LSCC cells. In addition, our investigation demonstrated that H19 shRNA exerted an inhibiting effect on autophagy and drug resistance by downregulating HMGB1 by targeting miR-107. Finally, the in vivo experiment revealed that LV-H19 shRNA strongly suppressed drug resistance compared with the usage of cisplatin individually. Taken together, our research indicated an H19-miR-107-HMGB1 axis in regulating the autophagy-induced drug resistance in LSCC in vitro and in vivo, providing novel targets for molecular-targeted therapy and broadening the research for LSCC.
机译:喉鳞状细胞癌(LSCC)是头颈部最常见的恶性肿瘤。目前LSCC的治疗都因耐药性增加而大大削弱。我们的研究旨在探讨长非编码RNA(lncRNA)H19对LSCC耐药性的影响。在我们的研究中,我们发现与对照组相比,LSCC组织和耐药细胞中的H19水平显著上调。此外,与对照组相比,耐药细胞中高迁移率族B1(HMGB1)的表达升高,microRNA107(miR-107)受到抑制。进一步研究表明,短发夹RNA(shRNA)对H19的干扰有效抑制了耐药细胞的高自噬水平和明显的耐药性。此外,miR-107被预测为H19的靶点,H19 shRNA对自噬和耐药性的抑制作用均被miR-107抑制剂逆转。此外,HMGB1被预测为LSCC细胞中miR-107的靶点,敲除HMGB1能够抑制LSCC细胞中的自噬和耐药性。此外,我们的研究表明,H19 shRNA通过靶向miR-107下调HMGB1,从而对自噬和耐药性产生抑制作用。最后,体内实验表明,与单独使用顺铂相比,LV-H19 shRNA强烈抑制耐药性。综上所述,我们的研究表明H19-miR-107-HMGB1轴在体外和体内调节LSCC自噬诱导的耐药性,为分子靶向治疗提供了新的靶点,并拓宽了LSCC的研究。

著录项

  • 来源
    《Cell biology international.》 |2021年第3期|共12页
  • 作者单位

    Chinese Peoples Liberat Army Gen Hosp Dept Otolaryngol Head &

    Neck Surg Hainan Branch Sanya;

    Chinese Acad Med Sci &

    Peking Union Med Coll Canc Hosp Dept Canc Prevent Beijing Peoples R China;

    Chinese Peoples Liberat Army Gen Hosp Dept Otolaryngol Head &

    Neck Surg Beijing Peoples R China;

    Chinese Peoples Liberat Army Gen Hosp Dept Otolaryngol Head &

    Neck Surg Hainan Branch Sanya;

    Chinese Peoples Liberat Army Gen Hosp Dept Otolaryngol Head &

    Neck Surg Hainan Branch Sanya;

    Chinese Peoples Liberat Army Gen Hosp Dept Otolaryngol Head &

    Neck Surg Beijing Peoples R China;

    Chinese Peoples Liberat Army Gen Hosp Dept Otolaryngol Head &

    Neck Surg Beijing Peoples R China;

    Liangxiang Hosp Dept Otolaryngol Beijing Peoples R China;

    Weifang Med Univ Dept Otolaryngol Head &

    Neck Surg Weifang Shandong Peoples R China;

    Weifang Med Univ Dept Otolaryngol Head &

    Neck Surg Weifang Shandong Peoples R China;

    Weifang Med Univ Dept Otolaryngol Head &

    Neck Surg Weifang Shandong Peoples R China;

    Chinese Peoples Liberat Army Gen Hosp Dept Otolaryngol Head &

    Neck Surg Hainan Branch Sanya;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

    autophagy; drug resistance; H19; HMGB1; LSCC; miRamp; 8208; 107;

    机译:自噬;耐药;HMGB1;LSCC;MIR&8208;107;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号